Friday 6 November 2026
Export PFE’s income statement to Excel — free account
Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −7.98%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
29.31
0.14
−0.48%
Follow PFE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
18.31 | 21.44 | 31.68 | 40.14 |
P/S ratio |
2.26 | 2.52 | 2.15 | 2.56 | |
P/FCF ratio |
17.10 | 18.40 | 13.47 | 14.80 | |
P/Operating CF |
26.46 | 61.11 | 164.35 | 30.24 | |
P/B ratio |
1.63 | 1.77 | 1.61 | 1.82 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.08 | 3.34 | 2.96 | 3.32 | |
EV/EBITDA |
9.25 | 10.00 | 9.25 | 10.48 | |
EV/Operating CF |
16.46 | 17.62 | 14.08 | 14.88 | |
EV/FCF |
23.28 | 24.32 | 18.53 | 19.20 | |
Quick Ratio |
0.69 | 0.75 | 0.74 | 0.90 | |
Current Ratio |
1.16 | 1.25 | 1.27 | 1.42 | |
Net Debt/EBITDA |
11.23 | 9.10 | 10.99 | 9.22 | |
Debt/Assets |
31.13% | 31.04% | 31.42% | 30.64% | |
Debt/Equity |
0.75 | 0.71 | 0.74 | 0.70 | |
Asset Turnover |
0.30 | 0.30 | 0.31 | 0.31 | |
Operating CF/Net income |
(3.25) | 0.97 | (3.37) | 1.66 | |
Capex/Depreciation |
(0.50) | (0.27) | (0.33) | (0.36) | |
Research and Development Expense of Revenue |
18.26% | 17.23% | 18.68% | 18.19% | |
Selling, General and Administrative Expense of Revenue |
23.71% | 20.49% | 22.69% | 19.77% | |
Intangible Assets out of Total Assets |
0.60 | 0.60 | 0.59 | 0.57 | |
Share Based Compensation of Revenue |
1.28% | 1.88% | 1.66% | 2.18% | |
Graham Net Nets |
(0.55) | (0.47) | (0.54) | (0.43) | |
Graham Number |
21.62 | 21.64 | 16.02 | 15.83 | |
Earnings Yield |
5.46% | 4.67% | 3.16% | 2.49% | |
Free Cash Flow Yield |
5.85% | 5.43% | 7.42% | 6.76% | |
Revenue per Share |
3.09 | 2.54 | 2.64 | 2.91 | |
Operating CF per Share |
0.94 | 0.46 | 0.15 | 0.94 | |
Capex per Share |
(0.15) | (0.08) | (0.09) | (0.10) | |
Free Cash Flow per Share |
0.79 | 0.38 | 0.05 | 0.84 | |
Cash per Share |
2.39 | 2.30 | 2.05 | 2.50 | |
Shareholders Equity per Share |
15.27 | 15.89 | 15.00 | 15.67 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.27 | 15.89 | 15.00 | 15.67 | |
Free Cash Flow |
4,503.00 | 2,179.00 | 302.00 | 4,802.00 | |
Working Capital |
5,914.00 | 8,474.00 | 8,712.00 | 13,283.00 | |
Capital Expenditures |
(845.00) | (436.00) | (533.00) | (573.00) | |
Net Current Asset Value |
(78,487.00) | (74,392.00) | (74,281.00) | (70,234.00) | |
EV/EBIT |
13.53 | 14.53 | 13.66 | 15.47 | |
Capex to Sales |
0.05 | 0.03 | 0.04 | 0.03 | |
Price to Operating Income |
9.93 | 10.99 | 9.93 | 11.92 | |
| Other line items | |||||
Average Receivables |
11,668.50 | 12,215.00 | 12,284.00 | 14,226.00 | |
Average Payables |
5,436.50 | 4,873.00 | 4,873.50 | 4,547.00 | |
Average Inventory |
10,752.50 | 10,759.50 | 10,807.00 | 10,745.00 | |
Average Assets |
210,778.00 | 207,823.00 | 203,613.00 | 206,637.50 | |
Average Common Equity |
87,636.00 | 90,520.00 | 87,252.00 | 91,198.50 |
Columns are period end dates · fundamentals updated 5 Nov 2026